Citius Oncology, Inc. CTOR Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Cash.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s cash & equivalents?
- Citius Oncology, Inc. (CTOR) reported cash & equivalents of $2.63M in Q1 2026.
- How has Citius Oncology, Inc.'s cash & equivalents changed year-over-year?
- Citius Oncology, Inc.'s cash & equivalents increased by 2350466.1% year-over-year, from $112 to $2.63M.
- What is the long-term trend for Citius Oncology, Inc.'s cash & equivalents?
- Over 3 years (2022 to 2025), Citius Oncology, Inc.'s cash & equivalents has grown at a 150.4% compound annual growth rate (CAGR), from $250K to $3.92M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.